Supplementary Figure 2. Progression-free survival and overall survival according to doxorubicin dose intensity administered. Progression-free survival according to RDDI in (A) intermediate-fit or frail patients (n = 87) and (B) fit patients (n = 162). Overall survival based on RDDI in (C) intermediate-fit or frail patients and (D) fit patients. RDDI, relative doxorubicin dose intensity; HR, hazard ratio; CI, confidence interval.